PARIS (Reuters) - Healthcare and clinical diagnostics company Novacyt announced more contract wins for its 'Primerdesign' product aimed at testing for the presence of the coronavirus, although the company suffered a minor setback in France.
Novacyt said it had total sales and confirmed orders worth 135 million euros ($150.3 million) for the product, with new wins in Zimbabwe and across Latin America.
Already a subscriber? Log in.
Win a prize this Mother's Day by subscribing to our annual plan now! T&C applies.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!